viewTiziana Life Sciences PLC

Tiziana Life Sciences wins significant patent for oral delivery of antibodies

Tiziana Life Sciences PLC's (LON:TILS)(NASDAQ:TLSA) Dr Kunwar Shailubhai tells Proactive London's Andrew Scott they've been granted a patent covering its proprietary platform technology for the oral administration of Foralumab - its proprietary fully human monoclonal antibody, and all other anti-CD3 monoclonal antibodies.

This first-in-class formulation allows Tiziana to work on drugs for Crohn’s, multiple sclerosis and Alzheimer’s disease that can be administered by mouth rather than requiring a painful intravenous line or injection.

The technology could also help eradicate many of the toxic side-effects of the intravenous use of mAbs such as Foralumab.

Quick facts: Tiziana Life Sciences PLC

Price: 192 GBX

Market: AIM
Market Cap: £323.6 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...



Tiziana Life Sciences PLC's clinical plan is shaping up says analyst Emma Ulker

Proactive Research analyst Emma Ulker says Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) is driving forwards at speed with the clinical development plan for its fully-human mAb TZLS-501 COVID-19 treatment. She adds that with GMP-grade manufacturing already underway they've appointed a number...

5 days, 9 hours ago

2 min read